Here's why Jim Cramer thinks Johnson & Johnson can keep running

Core Viewpoint - Johnson & Johnson's stock is performing well in 2023, with a year-to-date increase of over 23%, despite challenges in the broader healthcare sector [1][2]. Group 1: Stock Performance and Valuation - The stock is expected to reach its early 2022 all-time high of approximately $186, with potential to exceed $200 [1]. - The company has shown resilience against the backdrop of ongoing legal issues related to its talc products [1]. Group 2: Legal Strategy and Market Perception - Johnson & Johnson has shifted its legal strategy from seeking bankruptcy settlements to contesting lawsuits in court, which may have positively influenced market sentiment [2]. - There is a perception that plaintiff's lawyers may have overreached in their legal pursuits against the company [2]. Group 3: Business Segments and Growth Drivers - Johnson & Johnson is not solely a pharmaceutical company; it has a significant medical device segment that contributes to steady growth, particularly in cardiovascular products [2]. - The company has a robust drug portfolio, with thirteen drugs experiencing double-digit growth rates, which mitigates concerns over the impending patent cliff for its key drug, Stelara [3][4].